drugset
drugset / Trial / NCT02675556

Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression

NCT02675556 ↗

Phase 1 Terminated 1 enrolled Joshua M Hare
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is intended to evaluate the safety and potential efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion versus placebo in patients with Treatment Resistant Depression.

Timeline

Start
2017-10-31
Primary completion
2019-03-26
Completion
2019-03-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Rexlemestrocel-L Cell therapy 1e+08 cells Intravenous

Indications

No indication recorded.